DCPH News and Press, Deciphera Pharmaceuticals Inc. From 11/05/21

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Deciphera Pharmaceuticals, Inc. Shares Fell 73% After its INTRIGUE Phase 3 Clinical Study Failed to Meet its Primary Endpoint” Deciphera Pharmaceuticals, I...

Shares of Deciphera Pharmaceuticals Inc ( NASDAQ: DCPH ) tanked 75% on Friday morning after the U.S. firm said its INTRIGUE Phase III Clinical Study failed to meet the primary endpoint. The sharp decline wiped millions off its market cap that now stands at $565 million. Decipher...

Deciphera Pharmaceuticals (NASDAQ:DCPH) announces that its Qinlock treament failed to meet the primary endpoint in the company's late-stage trial of certain patients with gastrointestinal stromal tumor (GIST). The study did not meet the primary endpoint of improved progression-free ...

– Study Did Not Achieve Primary Efficacy Endpoint of Improved Progression-Free Survival Versus Standard of Care Sunitinib in Patients with Second-line GIST – – Conference Call to be Held Today at 8:00 AM ET – Deciphera Pharmaceuticals, Inc...

Start Time: 16:30 End Time: 17:30 Deciphera Pharmaceuticals, Inc. (DCPH) Q3 2021 Earnings Conference Call November 02, 2021, 16:30 PM ET Company Participants Steve Hoerter - President and CEO Dan Martin - Chief Commercial Officer Matt Sherman - Chief Medical Officer Tucker Kelly - CFO Jen Rob...

Image source: The Motley Fool. Deciphera Pharmaceuticals, inc (NASDAQ: DCPH) Q3 2021 Earnings Call Nov 2, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Deciphera Pharmaceuticals, inc (DCPH) Q3 2021 Earnings Call T...

The following slide deck was published by Deciphera Pharmaceuticals, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Deciphera Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call Presentation

Deciphera Pharmaceuticals (NASDAQ:DCPH): Q3 GAAP EPS of -$1.37 misses by $0.09. Revenue of $23.22M (+50.3% Y/Y) misses by $0.35M. Press Release For further details see: Deciphera Pharmaceuticals EPS misses by $0.09, misses on revenue

– Third Quarter 2021 Revenue of $23.2 Million, Including QINLOCK ® (ripretinib) Net Product Revenue of $21.7 Million – – Top-line Results from INTRIGUE Phase 3 Study of QINLOCK in Patients with Second-line Gastrointestinal Stromal Tumo...

Deciphera Pharmaceuticals (NASDAQ:DCPH) is scheduled to announce Q3 earnings results on Tuesday, November 2nd, after market close. The consensus EPS Estimate is -$1.25 (-10.6% Y/Y) and the consensus Revenue Estimate is $23.57M (+52.6% Y/Y). Over the last 3 months, EPS estimates have seen 0 up...